MTOR and cancer: The development of SRL has taught us many things, not least the unexpected role of mTOR in cancer, and with the “retrospectroscope” one wonders if SRL had been developed first would we be asking ourselves whether to use CNI that are, perhaps, easier to use but are associated with an unacceptable risk of post-transplant malignancy?